Journal article

Feedback of Individual Genetic Results to Research Participants: Is It Feasible in Europe?

Isabelle Budin-Ljosne, Deborah Mascalzoni, Sirpa Soini, Helena Machado, Jane Kaye, Heidi Beate Bentzen, Emmanuelle Rial-Sebbag, Flavio D'Abramo, Michal Witt, Genevieve Schamps, Visnja Katic, Dusanca Krajnovic, Jennifer R Harris

Biopreservation and Biobanking | MARY ANN LIEBERT, INC | Published : 2016

University of Melbourne Researchers

Grants

Awarded by Biobank Standardisation and Harmonisation for Research Excellence in the European Union (BioSHaRE-EU) program - European Union Seventh Framework Programme


Awarded by National Research and Innovation Platform for Personalized Cancer Medicine - Norwegian Research Council


Awarded by European Union Seventh Framework Programme


Awarded by Innovative Medicines Initiative project BTCure


Awarded by BioBanking and Molecular Resource Infrastructure of Sweden project - Swedish Research Council (BBMRI) LPC


Awarded by LegRegPCM (Legal Regulation of Information Processing relating to Personalized Cancer Medicine) - Norwegian Research Council


Awarded by European Research Council


Awarded by Biobank Norway - Norwegian Research Council


Awarded by Wellcome Trust


Funding Acknowledgements

The authors would like to thank Professor Heather Skirton, Plymouth University, for skillfully leading the OST workshop in Coimbra; the COST Action CHIP ME chairs of WG2 and WG3 for helping at collecting questionnaires; the COST Action CHIP ME members for their useful contributions; Professor Michael Hummel, Charite-Universitatsmedizin Berlin, Professor Jan Helge Solbakk, University of Oslo, and Professor Jean-Marc Hausman, Universite catholique de Louvain, for their comments. This article is based upon work from COST Action IS1303 "Citizen's Health through public-private Initiatives: Public health, Market and Ethical perspectives," and is supported by COST (European Cooperation in Science and Technology) (www.cost.eu); the Biobank Standardisation and Harmonisation for Research Excellence in the European Union (BioSHaRE-EU) program, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under Grant Agreement No. 261433; the National Research and Innovation Platform for Personalized Cancer Medicine funded by the Norwegian Research Council (NFR BIOTEK2021/ES495029); the European Union Seventh Framework Programme (FP7/20072013) under Grant Agreement No. 305444 (RD-Connect); the Innovative Medicines Initiative project BTCure (Grant Agreement No. 115142-1); the BioBanking and Molecular Resource Infrastructure of Sweden project financed by the Swedish Research Council (BBMRI) LPC (313010); LegRegPCM (Legal Regulation of Information Processing relating to Personalized Cancer Medicine) funded by the Norwegian Research Council (NFR BIOTEK2021/238999/O30); the European Research Council, under Grant Agreement No. 648608; and Biobank Norway, funded by the Norwegian Research Council (NFR 197443/F50). JK is funded under Wellcome Trust Award 096599/2/11/Z and the EU F7 project BIOSHARE.